Grant to CHOP funds personalized treatments for children with neuroblastoma

December 10, 2015

A new $1.5 million grant to The Children's Hospital of Philadelphia (CHOP) from Alex's Lemonade Stand Foundation (ALSF) supports an innovative approach to treating relapsed or refractory neuroblastoma, a high-risk childhood cancer.

CHOP researchers are launching a pediatric clinical trial with a dynamic design allowing them to quickly incorporate new treatments based on ongoing lab studies of evolving genetic changes in an individual patient's tumor. The researchers will match those gene changes with available drugs.

"This is the first time this strategy is being applied to a prospective clinical trial in children with cancer," said principal investigator Yael P. Mosse, M.D., a pediatric oncologist at CHOP. "Our hope is that this trial will change the paradigm of treating children with neuroblastoma, offer a new model for improving treatment of other childhood cancers, and serve as a blueprint for similar trials in other diseases."

The three-year Bio-Therapeutics Impact Award from ALSF seeks to strategically advance research-based treatment of neuroblastoma, an-often lethal childhood cancer that remains difficult to cure. Usually appearing as a solid tumor in the chest or abdomen, neuroblastoma accounts for a disproportionate share of cancer deaths in children, despite many recent improvements in therapy.

"Through the dedication and tireless efforts of Alex's Lemonade Stand Foundation's volunteers, we are attempting to make it possible for childhood cancer patients to become childhood cancer survivors," said Jay Scott, executive director of Alex's Lemonade Stand Foundation. "With every grant we are able to award, we are one step closer to finding those cures our daughter dreamed of."

The CHOP physician-scientists expect to begin the next-generation personalized neuroblastoma therapy (NEPENTHE) trial in 2016. "Next-generation refers to the most current gene-sequencing technology that provides us with better knowledge of the genetic and molecular features of an individual patient's tumor," said co-investigator John M. Maris, M.D., who leads CHOP's internationally prominent research laboratory focused on neuroblastoma.

"Our improved understanding of neuroblastoma biology and treatment will guide this trial and help us to continually design combination therapies that are potentially more effective and less toxic for our young patients," Maris added. The NEPENTHE trial will be a collaborative effort, enlisting the expertise of numerous other specialists throughout CHOP and other institutions. It will enroll children who have experienced a relapse of neuroblastoma or whose neuroblastoma did not respond to the initial treatment.
-end-
About The Children's Hospital of Philadelphia: The Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals and pioneering major research initiatives, Children's Hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country. In addition, its unique family-centered care and public service programs have brought the 535-bed hospital recognition as a leading advocate for children and adolescents. For more information, visit http://www.chop.edu.

Children's Hospital of Philadelphia

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.